epidemiologyЭпидемиология и ВакцинопрофилактикаEpidemiology and Vaccinal Prevention2073-30462619-0494«Numicom» LLC10.31631/2073-3046-2015-14-2-96-101epidemiology-45Research ArticleВАКЦИНОПРОФИЛАКТИКАVACCINAL PREVENTIONИзучение иммуногенности гибридных рекомбинантных белков на основе белков VP6 и VP8 ротавируса человека группы АImmunogenic Properties Studyoffusion Recombinant Proteins Based on VP6 and VP8 of Human Rotavirus AДуховлиновИ. В.DukhovlinovI. V.noemail@neicon.ruБогомоловаЕ. Г.BogomolovaE. G.noemail@neicon.ruФедороваЕ. А.FedorovaE. A.noemail@neicon.ruСимбирцевА. С.SimbirtsevA. S.noemail@neicon.ruФГУП «Государственный научно-исследовательский институт особо чистых биопрепаратов» ФМБА РоссииРоссияFederal State Unitary Enterprise «Research Institute of Highly Pure Biopreparations» of the Federal Biomedical Agency of Russian FederationRussian Federation20152004201514296101Copyright © Духовлинов И.В., Богомолова Е.Г., Федорова Е.А., Симбирцев А.С., 20152015Духовлинов И.В., Богомолова Е.Г., Федорова Е.А., Симбирцев А.С.Dukhovlinov I.V., Bogomolova E.G., Fedorova E.A., Simbirtsev A.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.epidemvac.ru/jour/article/view/45

Ротавирусная инфекция - основная причина возникновения тяжелой диареи, приводящей к дегидратации организма у младенцев и детей младше пяти лет. В течение жизни случаи ротавирусного гастроэнтерита могут повторяться. Ввиду отсутствия препаратов с прямым противоротавирусным действием самым эффективным способом борьбы с данным заболеванием считается своевременная вакцинация. Существующие противоротавирусные вакцины основаны на живых аттенуированных штаммах ротавируса человеческого и/или животного происхождения, которые размножаются в кишечнике человека, что может приводить к развитию различных осложнений. В данной работе изучали иммуногенность рекомбинантных гибридных белков VP6VP8 и FliCVP6VP8 - активных агентов кандидатной вакцины против ротавируса. В ходе исследования получены высокоочищенные препараты белков в нативных условиях, а также показана их высокая антигенная активность в экспериментах с лабораторными мышами линии Balb/c.

Rotavirus infection is the leading cause of severe acute diarrhea among young children worldwide. Contagion with these viruses often leads to severe dehydration of organism. Rotaviral gastroenteritis cases may repeat intra vitam. Because of the absence of drugs with direct action on rotavirus, a timely vaccination is considered the most effective way of this disease's control. Nowadays vaccines based on attenuated alive rotaviral strains are used for this purpose, which can result in different complications. In this work the immunogenicity of recombinant fusion proteins VP6VP8 and FliCVP6VP8 - the crucial active agents of the candidate vaccine against rotaviruses - was studied. As part of the study highly purified proteins preparationsin native state were obtained, their high antigenic activity in experiments with laboratory Balb/c mice was demonstrated.

ротавирусный гастроэнтеритвакцинарекомбинантные гибридные белкиrotavirus gastroenteritisvaccinerecombinant fusion proteinsReferencesShaw A.R. The rotavirus saga revisited. Ann. Rev. Med. 2013; 64: 165 - 174.Shaw A.R. The rotavirus saga revisited. Ann. Rev. Med. 2013; 64: 165 – 174.Schnagl R.D., Holmes I.H. Characteristics of the genome of human infantile enteritis virus (Rotavirus). J. Virol. 1976; 19 (1): 267 - 270.Schnagl R.D., Holmes I.H. Characteristics of the genome of human infantile enteritis virus (Rotavirus). J. Virol. 1976; 19 (1): 267 – 270.Rodriguez W.J., Kim H.W., Arrobio J.O., Brandt C.D., Chanock R.M., Kapikian A.Z. et al. Clinical features of acute gastroenteritis associated with human reovirus-like agent in infants and young children. J. Pediatr. 1977; 91 (2): 188 - 193.Rodriguez W.J., Kim H.W., Arrobio J.O., Brandt C.D., Chanock R.M., Kapikian A.Z. et al. Clinical features of acute gastroenteritis associated with human reovirus-like agent in infants and young children. J. Pediatr. 1977; 91 (2): 188 – 193.Dennehy P.H. Treatment and prevention of rotavirus infection in children. Curr. Infect. Dis. Rep. 2013; 15 (3): 242 - 250.Dennehy P.H. Treatment and prevention of rotavirus infection in children. Curr. Infect. Dis. Rep. 2013; 15 (3): 242 – 250.Parashar U.D., Nelson E.A.S., Kang G. Diagnosis, management, and prevention of rotavirus gastroenteritis in children. BMJ. 2013; 347: 29 - 34.Parashar U.D., Nelson E.A.S., Kang G. Diagnosis, management, and prevention of rotavirus gastroenteritis in children. BMJ. 2013; 347: 29 – 34.Духовлинов И.В., Богомолова Е.Г., Федорова Е.А. Создание гибридных рекомбинантных белков на основе VP6 и VP8 ротавируса человека группы А. Инфекция и иммунитет. 2014; 4: 229 - 234.Dukhovlinov I.V., Bogomolova E.G., Fedorova E.A., Simbirtsev A. S. Development of fusion recombinant proteins based on VP6 and VP8 of human rotavirus А. Russian Journal of Infection and Immunity. 2014; 4 (3): 229 – 234 (in Russian).Invitrogen. Ni-NTA purification system. User manual. Cat. Nos K950-01 K951-01 K952-01 K953-01 K954-01 R901-01 R901-10 R 901-15. 2006: 32.Invitrogen. Ni-NTA purification system. User manual. Cat. Nos K950-01 K951-01 K952-01 K953-01 K954-01 R901-01 R901-10 R 901-15. 2006: 32.Li M., Su Z.-G., Janson J.-C. In vitro protein refolding by chromatographic procedures. Protein Expr. Purif. 2004; 33 (1): 1 - 10.Li M., Su Z.-G., Janson J.-C. In vitro protein refolding by chromatographic procedures. Protein Expr. Purif. 2004; 33 (1): 1 – 10.Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970; 227 (5259): 680 - 685.Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970; 227 (5259): 680 – 685.Министерство здравоохранения СССР. Правила проведения работ с использованием экспериментальных животных; 1977: 755.The Ministry of Health of the USSR. Rules of work with experimental animals: 755. 1977 (in Russian).Dennehy P.H. Rotavirus vaccines: an overview. Clin. Microbiol. Rev. 2008; 21 (1): 198 - 208.Dennehy P.H. Rotavirus vaccines: an overview. Clin. Microbiol. Rev. 2008; 21 (1): 198 – 208.Bruijning-Verhagen P, Mangen M.J., Felderhof M., Hartwig N.G., van Houten M., Winkel L. et al. Targeted rotavirus vaccination of high-risk infants; a low cost and highly cost-effective alternative to universal vaccination. BMC Med. 2013; 11: 112.Bruijning-Verhagen P., Mangen M.J., Felderhof M., Hartwig N.G., van Houten M., Winkel L. et al. Targeted rotavirus vaccination of high-risk infants; a low cost and highly cost-effective alternative to universal vaccination. BMC Med. 2013; 11: 112.Ben-Yedidia T., Arnon R. Effect of pre-existing carrier immunity on the efficacy of synthetic influenza vaccine. Immunol. Lett. 1998; 64 (1): 9 - 15.Ben-Yedidia T., Arnon R. Effect of pre-existing carrier immunity on the efficacy of synthetic influenza vaccine. Immunol. Lett. 1998; 64 (1): 9 – 15.Balaram P., Kien P.K., Ismail A. Toll-like receptors and cytokines in immune responses to persistent mycobacterial and Salmonella infections. Int. J. Med. Microbiol. IJMM. 2009; 299 (3): 177 - 185.Balaram P., Kien P.K., Ismail A. Toll-like receptors and cytokines in immune responses to persistent mycobacterial and Salmonella infections. Int. J. Med. Microbiol. IJMM. 2009; 299 (3): 177 – 185.Weimer E.T. Ervin S.E., Wozniak D.J., Mizel S.B. Immunization of young African green monkeys with OprF epitope 8-OprI-type A- and B-flagellin fusion proteins promotes the production of protective antibodies against nonmucoid Pseudomonas aeruginosa. Vaccine. 2009; 27 (48): 6762 - 6769.Weimer E.T. Ervin S.E., Wozniak D.J., Mizel S.B. Immunization of young African green monkeys with OprF epitope 8-OprI-type A- and B-flagellin fusion proteins promotes the production of protective antibodies against nonmucoid Pseudomonas aeruginosa. Vaccine. 2009; 27 (48): 6762 – 6769.Honko A.N., Sriranganathan N., Lees C.J., Mizel S.B. Flagellin is an effective adjuvant for immunization against lethal respiratory challenge with Yersinia pestis. Infect. Immun. 2006;74 (2): 1113 - 1120.Honko A.N., Sriranganathan N., Lees C.J., Mizel S.B. Flagellin is an effective adjuvant for immunization against lethal respiratory challenge with Yersinia pestis. Infect. Immun. 2006;74 (2): 1113 – 1120.Mizel S.B., Bates J.T. Flagellin as an adjuvant: cellular mechanisms and potential. J. Immunol. Baltim. Md 1950. 2010; 185 (10): 5677 - 5682.Mizel S.B., Bates J.T. Flagellin as an adjuvant: cellular mechanisms and potential. J. Immunol. Baltim. Md 1950. 2010; 185 (10): 5677 – 5682.

The authors declare that there are no conflicts of interest present.